Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors
October 04, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, October 4, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex to Present at the Cantor Global Healthcare 2021 Conference
September 29, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 29, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm
September 29, 2021 01:00 ET
|
Addex Therapeutics
Type of dystonia characterized by involuntary spasms of the eyelid muscles can lead to substantial visual disturbance or functional blindness Ad Hoc Announcement Pursuant to Art. 53 LR Geneva,...
CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A
September 22, 2021 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Glenolden, PA and Geneva, Switzerland, September 22, 2021 (GLOBE NEWSWIRE) - The Charcot–Marie–Tooth Association (CMTA), the largest philanthropic funder of...
Addex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 8, 2021 - Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex to Present at the Swiss Biotech Day
September 02, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 2, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today...
Addex Reports 2021 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 05, 2021 01:00 ET
|
Addex Therapeutics
Strong cash and cash equivalents position at June 30, 2021 of CHF18.1M ($19.6M)Pivotal dipraglurant PD-LID study initiatedJanssen Pharmaceuticals started Phase 2 study in epilepsy with...
Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021
August 02, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 2, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and...
Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science
August 02, 2021 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering...
Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding
July 29, 2021 01:00 ET
|
Addex Therapeutics
IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022 Geneva, Switzerland, July 29, 2021 (GLOBE NEWSWIRE) - Ad Hoc Announcement...